Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Intermediate Risk Prostate Cancer × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 1020 Neoplasms 884 Carcinoma, Non-Small-Cell Lung 793 Prostatic Neoplasms 537 Neoplasm Metastasis 472 Leukemia, Myeloid, Acute 467 Lung Neoplasms 429 Melanoma 427 Colorectal Neoplasms 426 Multiple Myeloma 420 Pancreatic Neoplasms 339 Lymphoma 331 Ovarian Neoplasms 327 Recurrence 321 Leukemia 310 Lymphoma, Non-Hodgkin 308 Leukemia, Lymphocytic, Chronic, B-Cell 286 Precursor Cell Lymphoblastic Leukemia-Lymphoma 262 Brain Neoplasms 250 Carcinoma, Renal Cell 247 Head and Neck Neoplasms 240 Carcinoma, Hepatocellular 232 Glioblastoma 223 Myelodysplastic Syndromes 222 Lymphoma, Large B-Cell, Diffuse 213 Lymphoma, Follicular 210 Squamous Cell Carcinoma of Head and Neck 208 Colonic Neoplasms 179 Stomach Neoplasms 172 Rectal Neoplasms 164

Interventions

spartalizumab 1 Nivolumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03815942 2025-06-25

ADVANCE

University of Oxford

Phase 1/2 Terminated

23 enrolled 11 charts

Intermediate Risk Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡